A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men

Clinical Pharmacology in Drug Development - Tập 9 Số 7 - Trang 833-840 - 2020
Kei Sakamoto1, Shunji Matsuki2, Shin Irie2, Naoki Uchida3, Nobuya Hayashi1, Masato Horiuchi1, Song Ren4
1AstraZeneca K.K., Ofuka-cho, Kita-ku, Osaka, Japan
2SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan
3Department of Pharmacology, Division of Clinical Pharmacology, Showa University School of Medicine, Tokyo, Japan
4Quantitative Clinical Pharmacology, AstraZeneca, Gaithersburg, Maryland, USA

Tóm tắt

AbstractTezepelumab, a human immunoglobulin G2 monoclonal antibody against thymic stromal lymphopoietin, is currently under clinical development for the treatment of severe, uncontrolled asthma. This phase 1, randomized, placebo‐controlled, single‐ascending‐dose study assessed the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy Japanese men. Participants were assigned to 1 of 3 tezepelumab dose cohorts (35, 105, or 280 mg; n = 8 per cohort) and randomized (6:2) to receive a single subcutaneous dose of tezepelumab or placebo, with a follow‐up period of 84 to 112 days. The overall incidences and severities of treatment‐emergent adverse events were similar across tezepelumab doses and between the tezepelumab and placebo groups. Tezepelumab was absorbed slowly, reaching a maximum serum concentration (mean, 5.2‐39.7 µg/mL) after 7 to 10 days. Area under the concentration‐time curve (mean, 207.2‐1612.0 µg · day /mL) increased in an approximate dose‐proportional manner. Tezepelumab had a long terminal serum half‐life (mean, 23.9‐26.3 days) and a small apparent distribution volume, suggesting limited distribution into peripheral tissues. No participants developed anti‐tezepelumab antibodies. Single‐dose, subcutaneous administration of tezepelumab 35 to 280 mg resulted in an acceptable safety profile with linear pharmacokinetics in healthy Japanese men. No clear differences in tezepelumab safety and pharmacokinetics between Japanese and non‐Japanese populations were identified.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(17)33311-1

10.1016/S0140-6736(16)31678-6

10.1016/j.alit.2016.12.005

10.1016/j.rmed.2006.03.031

10.1378/chest.130.2.429

10.1016/j.jaci.2014.08.015

10.1111/j.1398-9995.2008.01724.x

10.1016/S0140-6736(08)61452-X

Corren J, 2013, Asthma phenotypes and endotypes: an evolving paradigm for classification, Discov Med, 15, 243

10.1097/MCP.0000000000000225

10.1097/ACI.0b013e32836093dd

10.1111/cea.12880

10.1084/jem.20062211

10.1002/eji.201041195

10.1038/ni805

10.1016/B978-0-12-404717-4.00004-4

10.4049/jimmunol.181.4.2790

10.4049/jimmunol.174.12.8183

10.1517/14728222.2014.915314

10.1056/NEJMoa1402895

10.1056/NEJMoa1704064

10.1002/cpt.1401

Roseti SL, 2017, Pharmacokinetic and safety evaluation of tezepelumab in adolescents with mild to moderate asthma, Am J Resp Crit Care Med, 195, A5103

Ly N, 2018, Exposure‐response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection, Eur Respir J, 52, PA1688

10.3201/eid1304.051195

10.1001/archinte.167.20.2255

10.1038/clpt.2008.170

10.2165/11531280-000000000-00000

10.4331/wjbc.v3.i4.73

10.2165/11535960-000000000-00000

Ryman JT, 2017, Pharmacokinetics of monoclonal antibodies, Pharmacometrics Sys Pharmacol, 5, 102

10.1002/cpdd.205

10.1016/j.jaip.2017.08.024

Thông tin
Thông tin xuất bản

Clinical Pharmacology in Drug Development

Tập 9 Số 7

833-840

Thông tin tác giả